Latest filings (excl ownership)
15-12G
Securities registration termination
5 Feb 24
EFFECT
Notice of effectiveness
31 Jan 24
EFFECT
Notice of effectiveness
31 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
POS AM
Prospectus update (post-effective amendment)
24 Jan 24
POS AM
Prospectus update (post-effective amendment)
24 Jan 24
8-K
Termination of a Material Definitive Agreement
24 Jan 24
25-NSE
Exchange delisting
24 Jan 24
8-K
Other Events
22 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
19 Dec 23
DEFA14A
Additional proxy soliciting materials
8 Dec 23
8-K
Other Events
8 Dec 23
DEFA14A
Additional proxy soliciting materials
30 Nov 23
8-K
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
30 Nov 23
DEFA14A
Additional proxy soliciting materials
21 Nov 23
8-K
Other Events
21 Nov 23
DEFM14A
Proxy related to merger
16 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
13 Nov 23
PREM14A
Preliminary proxy related to merger
3 Nov 23
8-K
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
26 Oct 23
DEFA14A
Additional proxy soliciting materials
17 Oct 23
DEFA14C
Additional information
5 Oct 23
DEFA14C
Additional information
5 Oct 23
DEFA14C
Additional information
5 Oct 23
DEFA14C
Additional information
5 Oct 23
DEFA14C
Additional information
5 Oct 23
DEFA14A
Additional proxy soliciting materials
5 Oct 23
8-K
Kyowa Kirin to Acquire Orchard Therapeutics
5 Oct 23
8-K
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
18 Sep 23
EFFECT
Notice of effectiveness
22 Aug 23
424B3
Prospectus supplement
21 Aug 23
CORRESP
Correspondence with SEC
17 Aug 23
UPLOAD
Letter from SEC
16 Aug 23
S-8
Registration of securities for employees
10 Aug 23
Latest ownership filings
SC 13G
Blue Owl Capital Holdings LP
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
FMR LLC
12 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
Beryl Capital Management LLC
8 Feb 24
4
Alicia Secor
24 Jan 24
4
JAMES A GERAGHTY
24 Jan 24
4
FRANK E THOMAS
24 Jan 24
4
Charles A Rowland Jr
24 Jan 24
4
Joanne T. Beck
24 Jan 24
4
Bobby Gaspar
24 Jan 24
4
Marc Dunoyer
24 Jan 24
4
Steven Altschuler
24 Jan 24
4
John T Curnutte
24 Jan 24
SC 13G
Beryl Capital Management LLC
16 Oct 23
4
Steven Altschuler
16 Jun 23
4
John T Curnutte
16 Jun 23
4
Marc Dunoyer
16 Jun 23
4
JAMES A GERAGHTY
16 Jun 23
4
Alicia Secor
16 Jun 23
4
Joanne T. Beck
16 Jun 23
4
Charles A Rowland Jr
16 Jun 23
SC 13G/A
FEDERATED HERMES, INC.
10 Apr 23
SC 13G
Deep Track Capital, LP
20 Mar 23
SC 13G
RA CAPITAL MANAGEMENT, L.P.
20 Mar 23
4
FRANK E THOMAS
14 Mar 23
4
FRANK E THOMAS
3 Mar 23
4
Bobby Gaspar
3 Mar 23
SC 13G/A
CHI Advisors LLC
13 Feb 23
4
FRANK E THOMAS
13 Feb 23
SC 13G/A
Flynn James E
10 Feb 23
SC 13G/A
Zentree Investments Ltd
9 Feb 23
SC 13G/A
FEDERATED HERMES, INC.
1 Feb 23
SC 13G/A
Zentree Investments Ltd
20 Dec 22
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Nov 22
4
FRANK E THOMAS
6 Oct 22
4
Bobby Gaspar
6 Oct 22
SC 13G
Zentree Investments Ltd
9 Sep 22
4
Alicia Secor
8 Jun 22
4
Joanne T. Beck
8 Jun 22